ALSUntangled #66: antimycobacterial antibiotics.

References

• Castanedo-Vazquez D, Bosque-Varela P, Sainz-Pelayo A, Riancho J. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. J Neurol. 2019;266:27–36.
   PubMed Web of Science ®Google Scholar
• Jubelt B, Berger JR. Does viral disease underlie ALS? Lessons from the AIDS pandemic. Neurology 2001;57:945–6.
   PubMed Web of Science ®Google Scholar
• Xue YC, Feuer R, Cashman N, Luo H. Enteroviral infection: the forgotten link to amyotrophic lateral sclerosis? Front Mol Neurosci. 2018; 11:63.
   PubMed Web of Science ®Google Scholar
• Matyja E, Laure-Kamionowska M. Post-polio syndrome and amyotrophic lateral sclerosis – similarities, differences and diagnostic dilemmas. http://postpolio.lublin.pl/PPS-conf/Abstract_PPS.ALS_en.pdf. Accessed June 25, 2018.
   Google Scholar
• Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 2001;57:995–1001.
   PubMed Web of Science ®Google Scholar
• Sini P, Dang TBC, Fais M, Galioto M, Padedda BM, Lugliè A, et al. Cyanobacteria, cyanotoxins, and neurodegenerative diseases: dangerous liaisons. Int J Mol Sci. 2021;22:8726.
   PubMed Web of Science ®Google Scholar
• Bradley WG, Mash DC. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph. Lateral Scler. 2009;10:7–20.
   PubMed Web of Science ®Google Scholar
• Nicolson GL, Nasralla MY, Haier J, Pomfret J. High frequency of systemic mycoplasmal infections in Gulf War veterans and civilians with Amyotrophic Lateral Sclerosis (ALS). J Clin Neurosci. 2002;9:525–9.
   PubMed Web of Science ®Google Scholar
• Ren J, Shen C, Che G. A rare case of tuberculosis with motor neuron disease. World J Surg Oncol. 2014;12:381–3.
   PubMed Web of Science ®Google Scholar
• Peer S, Nagaraj C, Mangalore S. Hybrid PET/MRI findings in a case of pulmonary and extra-pulmonary tuberculosis associated with motor-neuron disease-like illness – a coincidence or a causation?: A case report. Egypt J Radiol Nucl Med. 2021;52:1–6.
   Google Scholar
• Argyriou AA, Karanasios P, Papapostolou A, Loukopoulou P, Makridou A, Marangos M, et al. Neurobrucellosis presenting as clinically definite amyotrophic lateral sclerosis. Int J Neurosci. 2018; 128:686–3.
   PubMed Web of Science ®Google Scholar
• Moling O, Di Summa A, Capone L, Stuefer J, Piccin A, Porzia A, et al. Increased IL-17, a pathogenic link between hepatosplenic schistosomiasis and amyotrophic lateral sclerosis: a hypothesis. Case Reports Immunol. 2014; 2014:804761.
   PubMedGoogle Scholar
• Kuenstner JT, Chamberlin W, Naser SA, Collins MT, Dow CT, Aitken JM, et al. Resolution of Crohn’s disease and complex regional pain syndrome following treatment of paratuberculosis. World J Gastroenterol. 2015;21:4048–62.
   PubMed Web of Science ®Google Scholar
• Pierce ES. How did Lou Gehrig get Lou Gehrig’s disease? Mycobacterium avium subspecies paratuberculosis in manure, soil, dirt, dust and grass and amyotrophic lateral sclerosis (motor neurone disease) clusters in football, rugby and soccer players. Med Hypotheses. 2018;119:1–5.
   PubMed Web of Science ®Google Scholar
• Pierce ES. Mycobacterium avium subspecies paratuberculosis as a soil bacteria and ALS clusters in outdoor sports players. http://sciencetrends.com/mycobacterium-avium-subspecies-paratuberculosis-as-a-soil-bacteria-and-als-clusters-in-outdoor-sports-players/. Accessed January 3, 2022.
   Google Scholar
• Kuenstner JT, Naser S, Chamberlin W, Borody T, Graham DY, McNees A, et al. The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017. Front Public Health. 2017; 5:208.
   PubMed Web of Science ®Google Scholar
• Agrawal G, Aitken J, Hamblin H, Collins M, Borody TJ. Putting Crohn’s on the MAP: five common questions on the contribution of mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn’s Disease. Dig Dis Sci. 2021;66:348–58.
   PubMed Web of Science ®Google Scholar
• ALSUntangled Online. Future Reviews. http://www.alsuntangled.com/future-reviews/. Accessed June 15, 2022.
   Google Scholar
• Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol. 1999;58:459–71.
   PubMed Web of Science ®Google Scholar
• Parthasarathy G, Philipp MT. Review: apoptotic mechanisms in bacterial infections of the central nervous system. Front Immunol. 2012;3:306.
   PubMed Web of Science ®Google Scholar
• Spagnolo L, Törö I, D’Orazio M, O'Neill P, Pedersen JZ, Carugo O, et al. Unique features of the sodC-encoded superoxide dismutase from Mycobacterium tuberculosis, a fully functional copper-containing enzyme lacking zinc in the active site. J Biol Chem. 2004;279:33447–55.
   PubMed Web of Science ®Google Scholar
• Estévez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science. 1999;286:2498–500.
   PubMed Web of Science ®Google Scholar
• Brown GC. Nitric oxide and neuronal death. Nitric Oxide. 2010;23:153–65.
   PubMed Web of Science ®Google Scholar
• Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem. 1997;69:1936–44.
   PubMed Web of Science ®Google Scholar
• Abendaño N, Juste RA, Alonso-Hearn M. Anti-inflammatory and antiapoptotic responses to infection: a common denominator of human and bovine macrophages infected with Mycobacterium avium subsp. Biomed Res Int. 2013;2013:908348.
   PubMed Web of Science ®Google Scholar
• Abendaño N, Tyukalova L, Barandika JF, Balseiro A, Sevilla IA, Garrido JM, et al. Mycobacterium avium subsp. paratuberculosis isolates induce in vitro granuloma formation and show successful survival phenotype, common anti-inflammatory and antiapoptotic responses within ovine macrophages regardless of genotype or host of origin. PLoS One. 2014;9:e104238.
   PubMed Web of Science ®Google Scholar
• Kamala AN, Antia NH, Shetty VP. Study of the involvement of the sciatic nerve following inoculation with M. leprae and other mycobacteria in the mouse foot pad. Int J Leprosy Other Mycobacter Diseases 1984;52:506–14.
   PubMedGoogle Scholar
• Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother. 1992;36:2843–6.
   PubMed Web of Science ®Google Scholar
• Zanetti S, Molicotti P, Cannas S, Ortu S, Ahmed N, Sechi LA. "In vitro" activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn's disease and paratuberculosis. Ann Clin Microbiol Antimicrob. 2006;5:27.
   PubMedGoogle Scholar
• Beckler DR, Elwasila S, Ghobrial G, Valentine JF, Naser SA. Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn’s disease. World J Gastroenterol. 2008;14:2723–30.
   PubMed Web of Science ®Google Scholar
• Chiodini RJ. Bactericidal activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis. Antimicrob Agents Chemother. 1990;34:366–7.
   PubMed Web of Science ®Google Scholar
• Warren JB, Rees HC, Cox TM. Remission of Crohn’s disease with tuberculosis chemotherapy. N Engl J Med. 1986;314:182.
   PubMed Web of Science ®Google Scholar
• Hampson SJ, Parker MC, Saverymuttu SH, Joseph AE, McFadden JJ, Hermon-Taylor J. Quadruple antimycobacterial chemotherapy in Crohn’s disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther. 1989;3:343–52.
   PubMed Web of Science ®Google Scholar
• Schultz MG, Rieder HL, Hersh T, Riepe S. Remission of Crohn’s disease with antimycobacterial chemotherapy. Lancet. 1987;2:1391–2.
   PubMed Web of Science ®Google Scholar
• Picciotto A, Gesu GP, Schito GC, Testa R, Varagona G, Celle G. Antimycobacterial chemotherapy in inflammatory bowel disease. Biomed Pharmacother. 1989;43:141–3.
   PubMed Web of Science ®Google Scholar
• Wirostko E, Johnson L, Wirostko B. Crohn’s disease. Rifampin treatment of the ocular and gut disease. Hepatogastroenterology. 1987;34:90–3.
   PubMedGoogle Scholar
• Gupta S, Chaubey KK, Agarwal P, Kuenstner JT, Parashar D, Singh SV. Therapeutic management of Mycobacterium avium subspecies paratuberculosis infection with complete resolution of symptoms and disease in a patient with advanced inflammatory bowel syndrome. Mol Biol Rep. 2021;48:7013–20.
   PubMed Web of Science ®Google Scholar
• Williams SL, Harris NB, Barletta RG. Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. J Clin Microbiol. 1999;37:304–9.
   PubMed Web of Science ®Google Scholar
• Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol. 2008;28:265–8.
   PubMed Web of Science ®Google Scholar
• Krishnan MY, Manning EJ, Collins MT. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother. 2009;64:310–6.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol. 1999;181:2044–9.
   PubMed Web of Science ®Google Scholar
• Lamont EA, Dillon NA, Baughn AD. The bewildering antitubercular action of pyrazinamide. Microbiol Mol Biol Rev. 2020;84:e00070-19.
   PubMed Web of Science ®Google Scholar
• Honap S, Johnston E, Agrawal G, Al-Hakim B, Hermon-Taylor J, Sanderson J. Anti-Mycobacterium paratuberculosis (MAP) therapy for Crohn’s disease: an overview and update. Frontline Gastroenterol. 2021;12:397–403.
   PubMed Web of Science ®Google Scholar
• Alcedo KP, Thanigachalam S, Naser SA. RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn’s disease associated with Mycobacterium paratuberculosis. Gut Pathog. 2016; 8:32.
   PubMed Web of Science ®Google Scholar
• Qasem A, Safavikhasraghi M, Naser SA. A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn’s disease associated with Mycobacterium avium subspecies paratuberculosis. Gut Pathog. 2016; 8:45.
   PubMed Web of Science ®Google Scholar
• Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, et al. Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications. Expert Opin. Biol. Ther. 2019;19:79–88.
   PubMed Web of Science ®Google Scholar
• Agrawal G, Clancy A, Sharma R, Huynh R, Ramrakha S, Borody T. Targeted combination antibiotic therapy induces remission in treatment-naive Crohn’s disease: a case series. Microorganisms 2020;8:371.
   PubMed Web of Science ®Google Scholar
• Borody TJ, Bilkey S, Wettstein AR, Leis S, Pang G, Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig Liver Dis. 2007;39:438–44.
   PubMedGoogle Scholar
• Agrawal G, Hamblin H, Clancy A, Borody T. Anti-mycobacterial antibiotic therapy induces remission in active Paediatric Crohn’s Disease. Microorganisms 2020;8:1112.
   PubMed Web of Science ®Google Scholar
• Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn’s strictures open with anti-mycobacterial antibiotic therapy: a retrospective review. World J Gastrointest Endosc. 2020;12:542–54.
   PubMed Web of Science ®Google Scholar
• Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis 2009;15:17–24.
   PubMed Web of Science ®Google Scholar
• Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–32.
   PubMed Web of Science ®Google Scholar
• Chopra S, Matsuyama K, Hutson C, Madrid P. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother. 2011;66:1533–6.
   PubMed Web of Science ®Google Scholar
• Parrish N, Vadlamudi A, Goldberg N. Anaerobic adaptation of Mycobacterium avium subspecies paratuberculosis in vitro: similarities to M. tuberculosis and differential susceptibility to antibiotics. Gut Pathog. 2017; 9:34.
   PubMed Web of Science ®Google Scholar
• World Health Organization – Regional Office for South-East Asia. Guidelines for the diagnosis, treatment and prevention of leprosy (2017).
   Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
   PubMed Web of Science ®Google Scholar
• Toronto General Hospital Immunodeficiency Clinic. Rifabutin. http://hivclinic.ca/main/drugs_fact_files/rifabutin.pdf. Accessed May 6, 2022.
   Google Scholar
• Griffith DE, Brown BA, Girard WM, Wallace RJ. Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995;21:594–8.
   PubMed Web of Science ®Google Scholar
• Rihani HT, Smith WM. Drug-induced uveitis: part 2: Cidofovir, rifabutin, sulfonamides, bisphosphonates, fluoroquinolones, intravitreal anti-vascular endothelial growth factor, and topical antiglaucoma medications. Adv Ophthalmol Optometry 2020;2020:5307–30.
   Google Scholar
• London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3:18–43.
   PubMedGoogle Scholar
• Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf. 1993;8:350–64.
   PubMed Web of Science ®Google Scholar
• Svanstrom H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ. 2014;349:g4930. 349g4930.
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014;4:e004143.
   PubMed Web of Science ®Google Scholar
• MedLine Plus – National Library of Medicine (US). Metronidazole. http://medlineplus.gov/druginfo/meds/a689011.html. Accessed April 18, 2022.
   Google Scholar
• Sorensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. J Neurol. 2020;267:1–13.
   PubMed Web of Science ®Google Scholar
• McGrath NM, Kent‐Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. Clin Exp Ophthalmol. 2007;35:585–6.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019;26:1355–61.
   PubMed Web of Science ®Google Scholar
• Drugs.com. Rifabutin prices, coupons, and patient assistance programs. http://www.drugs.com/price-guide/rifabutin#:∼:text = The%20cost%20for%20rifabutin%20oral,not%20valid%20with%20insurance%20plans. Accessed April 18, 2022.
   Google Scholar
• Drugs.com. Clarithromycin prices, coupons, and patient assistance programs. https://www.drugs.com/price-guide/clarithromycin. Accessed April 19, 2022.
   Google Scholar
• World Health Organization. World Health Organization Model List of Essential Medicines. http://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf.
   Google Scholar
• Nontuberculous Mycobacteria Info & Research Inc. Access to clofazimine. http://ntminfo.org/your-treatment-the-emphasis-on-you-2/. Accessed April 17, 2022.
   Google Scholar
• Drugs.com. Metronidazole prices, coupons, and patient assistance programs. http://www.drugs.com/price-guide/metronidazole. Accessed April 19, 2022.
   Google Scholar